Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch
Eli Lilly has amassed a stockpile of soon-to-be-launched drugs and related materials, primarily its oral GLP-1 candidate orforglipron, worth more than half a billion dollars …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
